[Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture].
OBJECTIVE
To assess efficacy and safety of alendronate sodium treatment in osteoporosis patients with hip fracture.


METHODS
One year randomized, double-blind clinical trial was carried out in 77 osteoporosis patients with hip fracture. The bone mineral density (BMD) in lumbar spine (L(2 - 4)), femoral neck (Neck), Wards triangle (Wards) and great trochanter (Troch) was measured by dual energy x-ray absorptiometer (DEXA).


RESULTS
In our study, alendronate sodium induced marked increases in BMD of the L(2 - 4) (7.0% +/- 13.0%), Neck (7.3% +/- 11.1%), Wards (4.6% +/- 5.9%), Troch (4.5% +/- 3.2%) (mean +/- s) versus decreases of 2.0% +/- 4.5%, -0.9% +/- 6.9%, 3.6% +/- 4.9% and 1.14% +/- 6.0% with placebo (P < 0.05). Blood Ca, P, ALP, BGP and Urine Pyd/C were no significant difference between before and after therapy. There were usually mild and transient side-effect, such as gastrointestinal symptoms.


CONCLUSIONS
Alendronate is an efficacy and safety drug in treatment of osteoporosis.
Qiu
Gui-xing
GX
Department of Orthopeadic, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Wu
Zhi-hong
ZH
Shen
Jian-xiong
JX
Luo
Xian-zheng
XZ
Tang
Hai
H
Wang
Yi-peng
YP
Weng
Xi-sheng
XS
Yang
Xin-yu
XY
Lin
Jin
J
Jin
Jin
J
Zhao
Hong
H
Tian
Ye
Y
Zhang
Jian-guo
JG
D015502:Absorptiometry, Photon; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D002118:Calcium / Q000097:blood; D016022:Case-Control Studies; D004311:Double-Blind Method; D005260:Female; D006620:Hip Fractures / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000410:Alanine Transaminase; D002118:Calcium; D019386:Alendronate